Contact l Sitemap

home industries issues reasearch weblog press

Home  » Industries » Pharmaceuticals

CorpWatch Exclusives

Eli Lilly Raised U.S. Prices Of Diabetes Drug 700 Percent Over 20 Years
by Pratap ChatterjeeCorpWatch Blog
November 2nd, 2016
Eli Lilly, an Indianapolis based company, that has sold insulin products to diabetes patients since 1921, has quietly raised some U.S. prices 700 percent in the last 20 years by marketing so-called improved versions to consumers. Novo Nordisk, a Danish company, has also profited handsomely from this practice.

Six Novartis Executives Charged In Illegal Drug Rebate Scheme In South Korea
by Richard SmallteacherSpecial to CorpWatch
August 11th, 2016
Six executives of Swiss pharmaceutical giant Novartis have been indicted in a South Korean bribery scandal. The indictments follow similar charges in China, Turkey and the U.S. and allegations of falsifying drug trial data in Japan. Korean prosecutors have recommended that Novartis sales be suspended for six months.

Gilead Avoided $10 Billion In Taxes On Over Priced Hepatitis C Drugs
by Richard SmallteacherSpecial to CorpWatch
July 13th, 2016
Gilead Sciences Inc., a California based pharmaceutical company, has avoided paying $10 billion in taxes by moving its patents to Ireland. This is despite the fact that one of its most profitable drugs was developed with U.S. taxpayer money, according to a new report from Americans for Tax Fairness.

Ovarian Cancer Victims Win Talcum Powder Lawsuits Against Johnson & Johnson
by Richard SmallteacherCorpWatch Blog
April 4th, 2016
Johnson & Johnson has been sued by over 1,200 women who blame the company's talcum powder products for their ovarian cancer. Not only are U.S. courts beginning to agree with them, juries have started to award victims millions of dollars in compensation.

Sun Pharma, India's Biggest Drug Producer, Violated Manufacturing Rules
by Richard SmallteacherCorpWatch Blog
December 25th, 2015
Sun Pharma, India's biggest drug manufacturer, has been sent a warning letter about violations of manufacturing regulations at its Halol plant in Gujarat by the United States Food and Drug Administration (FDA). Indian companies supply as much as 40 percent of the drugs sold in the U.S.

U.S. Doctors Associations Cancel Collaborations With Coca-Cola After Protests
by Pratap ChatterjeeCorpWatch Blog
October 1st, 2015
Three major U.S. medical associations - the American Academy of Family Physicians, the American Academy of Pediatrics and the American College of Cardiology - have bowed to pressure from activist doctors to stop accepting corporate donations from Coca-Cola. The campaigners say Coke exerted undue influence over the medical groups.

Drugs Tested By GVK Biosciences Banned From European Union
by Pratap ChatterjeeCorpWatch Blog
July 27th, 2015
Hundreds of drugs tested in India have been banned from sale in the European Union after French inspectors found flaws in clinical trials conducted by GVK Biosciences, a company based in Hyderabad. The Indian government has threatened to take legal action against the ban under international trade rules.

DaVita Pays $895 Million To Settle Kidney Treatment Fraud Claims
by Richard SmallteacherCorpWatch Blog
May 14th, 2015
DaVita, a company that provides health care to patients with kidney problems, has agreed to pay $495 million to settle whistleblower complaints that the company conspired to overcharge the U.S. government. This is in addition to the $400 million that the company had to pay out last year.

Actavis Sued To Stop Forced Switch To New Alzheimer's Drug
by Richard SmallteacherCorpWatch Blog
September 16th, 2014
Actavis, the world's third-largest generic drug manufacturer, has been sued by New York state to prevent it from forcing patients to take a new version of a popular Alzheimer's drug. The company is attempting to hook patients on an extended release version before its U.S. patent expires next year.

Gilead Sciences Under Investigation for Over Charging for Hepatitis C Pill
by Pratap ChatterjeeCorpWatch Blog
July 21st, 2014
Gilead Sciences of San Francisco is under investigation by the U.S. Senate Finance Committee for charging $84,000 for a 12 week course of a new drug to treat hepatitis C. Gilead sells the exact same course for $900 in poor countries like Egypt and India.

Big Pharma Abandons New Tuberculosis Drug Research
by Fatima HansiaCorpWatch Blog
April 1st, 2014
Three major pharmaceutical companies - AstraZeneca, Johnson & Johnson and Pfizer - have recently delayed or canceled clinical trials for testing tuberculosis (TB) drugs in India and South Africa. Activists say this is symbolic of a trend by Big Pharma to abandon research into diseases that affect poor people.

Bayer CEO Says Drugs Developed For “Western Patients Who Can Afford It”
by Pratap ChatterjeeCorpWatch Blog
February 3rd, 2014
Bayer, the German pharmaceutical giant, is in hot water after CEO Marijn Dekkers told a Financial Times conference that the company designed medicines “for western patients who can afford it” not for the “Indian market.” The company has been critical of the Indian governments efforts to make cheap generic drugs available locally.

Bumper Year for Corporate Donations Reveals Profit Motives
by Rick CohenCorpWatch Blog
September 10th, 2013
U.S. corporations gave away $18.15 billion in charitable donations in 2012 – a combination of cash, grants, and in-kind goods - up 12.2 percent in nominal terms over the previous year. A closer look reveals profit motives, notably for pharmaceutical companies and retail chain Wal-Mart.

GlaxoSmithKline Alleged to Pay Bribes in China
by Pratap ChatterjeeCorpWatch Blog
July 15th, 2013
GlaxoSmithKline (GSK) has been accused of bribing doctors in China in order to boost sales. Chinese government officials say they have uncovered evidence of a bribery scheme involving 700 travel agencies who were used to funnel as much as three billion yuan ($480 million) in payments.

Myriad Loses Patent to Breast Cancer Genetic Test
by Richard SmallteacherCorpWatch Blog
June 13th, 2013
Myriad Genetics has lost its right to be the exclusive U.S. commercial provider of genetic screening tests for breast cancer or ovarian cancer. The American Civil Liberties Union (ACLU), which sued the company, claimed that the patent would limit scientific research as well as health care options for women.

Ranbaxy Pays $500 Million Fine for Selling Bad Batches of Generic Medicines
by Pratap ChatterjeeCorpWatch Blog
May 14th, 2013
Ranbaxy, a subsidiary of Japanese pharmaceutical company Daiichi Sankyo, has paid a $500 million fine and pled guilty to selling adulterated drugs manufactured in India. The settlement comes 16 months after the company signed an agreement with U.S. authorities to change its ways.

Medical Trial Data Activists Score Win Over Glaxo
by Pratap ChatterjeeCorpWatch Blog
February 7th, 2013
All data on completed medical experiments are to be made available to the general public by GlaxoSmithKline, the biggest UK pharmaceutical company. The announcement is a major win for the AllTrials campaign mounted by healthcare activists as well as researchers that has gathered widespread support.

UK Pathology Labs Suffer In Quality Under Serco Management
by Puck LoCorpWatch Blog
October 24th, 2012
Privatization of major medical laboratories from the National Hospital Service (NHS) in Britain has led to a dramatic decline in service quality, according to a “Transforming Pathology, the Serco way,” a recent report from UK-based researchers Corporate Watch.

Indian Supreme Court to Hear Novartis “Patents Versus Patients” Case
by Pratap ChatterjeeCorpWatch Blog
August 21st, 2012
Novartis, the Swiss pharmaceutical company, will appear before the Indian Supreme Court Wednesday to appeal against a patent rejection for a popular cancer drug. A decision in favor of the company could have a devastating impact on cheap supplies of many kinds of generic drugs for poor patients.

Pfizer Admits Bribery in Eight Countries
by Pratap ChatterjeeCorpWatch Blog
August 8th, 2012
Pharmaceutical giant Pfizer has agreed to pay a total of $60.2 million in penalties to U.S. government regulators to settle documented charges of bribery in eight countries: Bulgaria, China, Croatia, Czech Republic, Italy, Kazakhstan, Russia, and Serbia.

Displaying 1-20 of 34  
Next >> 
Last Page » 
« Show Complete List »